Last reviewed · How we verify
NCT07523282: AID
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Phase 1 trial testing HN2302 Injection in Autoimmune Disease in 12 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Shenzhen MagicRNA Biotechnology Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 28 April 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- HN2302 Injection — full drug profile →
Conditions studied
- Autoimmune Disease — all drugs for Autoimmune Disease →
- Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →
- Systemic Sclerosis (SSc) — all drugs for Systemic Sclerosis (SSc) →
Sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd — full company profile →
Who can join
Adults 18 to 69, any sex, with Autoimmune Disease or Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07523282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autoimmune Disease
Currently open trials in the same condition.
- NCT07366866 — A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. · Phase 1 · recruiting
- NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
- NCT06983964 — Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases · NA · recruiting
- NCT06993493 — Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases · NA · recruiting
- NCT04751396 — Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Imm · recruiting
Other Shenzhen MagicRNA Biotechnology Co., Ltd trials
Trials by the same sponsor.
- NCT06965309 — Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG) · NA · terminated
- NCT06801119 — Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07523282 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen MagicRNA Biotechnology Co., Ltd
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07523282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing